Pliant Therapeutics vs Arcus Biosciences
PLRX and RCUS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PLRX and RCUS compare
Arcus Biosciences is the larger company, worth 50 times as much as Pliant Therapeutics ($2.4B against $48.2M).
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PLRX | RCUS |
|---|---|---|
| Size and price | ||
| Market cap | $48.2M | $2.4B |
| Share price | $0.778 | $18.80 |
| Change, 1 year | −52.0% | −3.4% |
| Change, 5 years | −94.8% | −60.5% |
| Beta (5Y) | 1.02 | 1.43 |
| Employees | 49 | 601 |
| StockData Score | ||
| Total score | 3 | 3 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 2 (better) |
| Performance score | 1 (better) | 0 |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 23.9× |
| P/B | 0.3× (better) | 6.7× |
| FCF yield | −147% | −19.5% (better) |
| Fair value | – | $5.97 |
| Margin of safety | – | −215% |
| Growth | ||
| Revenue growth (TTM) | – | −58.3% |
| Revenue growth, 5Y average | – | 25.9% |
| Profitability | ||
| Operating margin | – | −475% |
| Net margin | – | −453% |
| FCF margin | – | −466% |
| Return on equity | −50.3% (better) | −114% |
| Financial health | ||
| Interest coverage | −102.5× | −43.2× (better) |
| Current ratio | 9.90 (better) | 3.34 |
| Altman Z-score | −6.74 | −1.12 (better) |
| Piotroski F-score | 2 (better) | 1 |
| Dividends and buybacks | ||
| Dividend yield | 0.00% | – |
| Years of dividend growth | 0 | – |
| Buyback yield | – | −11.7% |
| Shareholder yield | 0.00% (better) | −11.7% |
| Ownership | ||
| Held by institutions | 77.7% | 96.3% |
| Held by insiders | 13.0% | 31.7% |
| Insider net buying, 12 months | −$164K (better) | −$9.3M |
| Short interest, % of float | 9.1% | 15.2% |
Go deeper
- PLRX stock overview
- PLRX income statement
- PLRX valuation and score
- RCUS stock overview
- RCUS income statement
- RCUS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.